SCHEMBL715265

SCHEMBL715265

Cc1nc(N)nc(NC(C)c2cc3cccc(Cl)c3nc2N2CCN(C(=O)C3CC3)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.42
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
SOS1 Q07889 3/20 0.38
PIK3R2 O00459 1/20 0.38
PIK3CD O00329 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
P2RX3 P56373 1/20 0.36
P2RY12 Q9H244 1/20 0.36
MTNR1B P49286 1/20 0.35
CNR1 P21554 1/20 0.35
TP53 P04637 1/20 0.35
JUN P05412 1/20 0.34
MAPK10 P53779 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715264 1.00 MAPT (0.42) MAPTLMNAPOLBSOS1PIK3R2
SCHEMBL714861 0.91 PIK3CD (0.42) MAPTPIK3R2PIK3CDP2RX3P2RY12
SCHEMBL714860 0.91 PIK3CD (0.42) MAPTPIK3R2PIK3CDP2RX3P2RY12
SCHEMBL714203 0.88 MAPT (0.42) MAPTLMNAPOLBSOS1PIK3CD
SCHEMBL714202 0.88 MAPT (0.42) MAPTLMNAPOLBSOS1PIK3CD
SCHEMBL717268 0.88 PIK3CD (0.41) PIK3R2PIK3CDP2RX3CNR1
SCHEMBL717269 0.88 PIK3CD (0.41) PIK3R2PIK3CDP2RX3CNR1
SCHEMBL717892 0.86 LRRK2 (0.39) SOS1PIK3R2PIK3CDCNR1TSHR
SCHEMBL717891 0.86 LRRK2 (0.39) SOS1PIK3R2PIK3CDCNR1TSHR
SCHEMBL17530765 0.85 ALDH1A1 (0.40) MAPTLMNAPOLBSOS1PIK3R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 MAPT 1229/4885LMNA 4722/4885POLB 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.